Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:SYK
Previous Symbol
CUSIP86366710
Phone269-389-2600
Debt
Debt-to-Equity Ratio0.60
Current Ratio1.91
Quick Ratio1.21
Price-To-Earnings
Trailing P/E Ratio26.53
Forward P/E Ratio23.65
P/E Growth2.31
Sales & Book Value
Annual Sales$12.44 billion
Price / Sales5.18
Cash Flow$8.5186 per share
Price / Cash20.21
Book Value$26.35 per share
Price / Book6.53
Profitability
EPS (Most Recent Fiscal Year)$6.49
Net Income$1.02 billion
Net Margins9.31%
Return on Equity28.00%
Return on Assets12.26%
Miscellaneous
Employees33,000
Outstanding Shares374,190,000
Market Cap$62.80 billion
OptionableOptionable
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker announced a quarterly dividend on Wednesday, September 19th. Shareholders of record on Friday, September 28th will be paid a dividend of $0.47 per share on Wednesday, October 31st. This represents a $1.88 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Thursday, September 27th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) issued its quarterly earnings results on Thursday, October, 25th. The medical technology company reported $1.69 EPS for the quarter, topping the Zacks' consensus estimate of $1.68 by $0.01. The medical technology company had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.26 billion. Stryker had a return on equity of 28.00% and a net margin of 9.31%. View Stryker's Earnings History.
When is Stryker's next earnings date?
What guidance has Stryker issued on next quarter's earnings?
Stryker issued an update on its fourth quarter 2018 earnings guidance on Thursday, October, 25th. The company provided earnings per share (EPS) guidance of $2.13-2.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.13. Stryker also updated its FY 2018 guidance to $7.25-7.30 EPS.
What price target have analysts set for SYK?
22 brokerages have issued twelve-month price targets for Stryker's shares. Their forecasts range from $165.00 to $200.00. On average, they anticipate Stryker's stock price to reach $181.95 in the next twelve months. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Price Targets for Stryker.
What is the consensus analysts' recommendation for Stryker?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. Needham & Company LLC analysts commented, "We attended at its Orthopaedics facility in on 11/8/18. We highlight some of our take-aways from the event below." (11/9/2018)
- 2. According to Zacks Investment Research, "Stryker exited the third quarter on a mixed note, with earnings beating estimates and revenues missing the same. The company continues to gain from its flagship Mako Total Knee platform, which drove its core Orthopaedic segment. In fact, the company witnessed solid growth in Mako robot installations in the quarter. Surging domestic sales is another positive. Moreover, solid performance in emerging markets and Europe paints a bright picture. Solid expansion in operating margin is encouraging as well. A raised guidance for 2018 buoys optimism. Stryker outperformed the industry in a year’s time. On the flip side, gross margin has been declining. Total debt on the balance sheet remains unchanged, adding to the company’s woes. The Trauma & Extremities business had moderate growth and was affected by softness in the market and product supply issues. Stiff competition is likely to mar Stryker’s prospects." (10/30/2018)
- 3. BTIG Research analysts commented, "Adding Photonics to its Instrument Offerings This morning, Stryker announced the acquisition of Invuity (IVTY, Not a share in all cash, for a deal value of ~$190M. With TTM sales of $40.8M, the deal multiple comes in at ~4.7x, in line with previous SYK acquisitions. The IVTY portfolio of photonic illuminated retractors will add to Stryker’s product offering in a variety of areas such as nipple- sparing mastectomies, anterior hip procedures, as well as general surgery and other areas. We believe the IVTY products will compliment Stryker’s existing visualization and illumination product portfolio modestly. That said, while IVTY offered a novel technology, the company was challenged to independently gain broader adoption as a stand-alone technology beyond a specific subset of procedures where proper illumination was not achieved with overhead exterior surgical field lighting." (9/12/2018)
Has Stryker been receiving favorable news coverage?
News headlines about SYK stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stryker earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned press coverage about the medical technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN) and ICU Medical (ICUI).
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman & CEO (Age 53)
- Mr. Timothy J. Scannell, Pres & COO (Age 53)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 56)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 56)
- Mr. David K. Floyd, Group Pres & Advisor to the CEO (Age 57)
Who are Stryker's major shareholders?
Stryker's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.39%), Greenleaf Trust (6.08%), Capital Research Global Investors (3.88%), Bank of New York Mellon Corp (2.03%), Massachusetts Financial Services Co. MA (1.90%) and Franklin Resources Inc. (1.53%). Company insiders that own Stryker stock include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Roch Doliveux, Ronda E Stryker, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which major investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., BlackRock Inc., TIAA CREF Investment Management LLC, Mitsubishi UFJ Trust & Banking Corp, Bank of New York Mellon Corp and PNC Financial Services Group Inc.. Company insiders that have sold Stryker company stock in the last year include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, William E Berry Jr and Yin C Becker. View Insider Buying and Selling for Stryker.
Which major investors are buying Stryker stock?
SYK stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Winslow Capital Management LLC, Alliancebernstein L.P., HealthCor Management L.P., Mackenzie Financial Corp, Schroder Investment Management Group and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $172.16.
How big of a company is Stryker?
Stryker has a market capitalization of $62.80 billion and generates $12.44 billion in revenue each year. The medical technology company earns $1.02 billion in net income (profit) each year or $6.49 on an earnings per share basis. Stryker employs 33,000 workers across the globe.
What is Stryker's official website?
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
